To overcome low survival/retention rate or insignificant long-term efficacy of the treatment supposedly achieved field breakthrough for neurological disorders, studies using that stem cell as a carrier of gene therapy combine its curative effects, e.g., which are modified in vitro with transcriptional regulation factor (such as by Nurr1 of nuclear receptor superfamily, human gene name: NR4A2). The gene discussed is NR4A2; the disease is nervous system disorder.